Sera Prognostics (NASDAQ:SERA) Stock Rating Upgraded by Jefferies Financial Group

Sera Prognostics (NASDAQ:SERA) was upgraded by research analysts at Jefferies Financial Group to a “strong-buy” rating in a note issued to investors on Monday,Zacks.com reports.

SERA has been the subject of a number of other reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Sera Prognostics in a report on Monday. Wall Street Zen raised shares of Sera Prognostics from a “sell” rating to a “hold” rating in a research note on Saturday, October 25th. One investment analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $5.00.

Sera Prognostics Stock Up 1.6%

Shares of Sera Prognostics stock traded up $0.06 on Monday, hitting $3.62. The company’s stock had a trading volume of 6,251 shares, compared to its average volume of 167,715. Sera Prognostics has a 52-week low of $1.37 and a 52-week high of $9.13. The firm has a fifty day moving average price of $3.20 and a 200-day moving average price of $2.85. The company has a market capitalization of $139.56 million, a P/E ratio of -4.70 and a beta of 0.97.

Sera Prognostics (NASDAQ:SERA) last posted its earnings results on Thursday, November 13th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.03. Sera Prognostics had a negative net margin of 34,343.16% and a negative return on equity of 41.69%. The firm had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.10 million. As a group, analysts expect that Sera Prognostics will post -0.96 earnings per share for the current year.

Insider Buying and Selling

In other Sera Prognostics news, CEO Zhenya Lindgardt sold 28,215 shares of the stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $3.04, for a total transaction of $85,773.60. Following the transaction, the chief executive officer owned 768,081 shares of the company’s stock, valued at $2,334,966.24. This trade represents a 3.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders have sold a total of 50,587 shares of company stock worth $157,528 over the last ninety days. Corporate insiders own 15.80% of the company’s stock.

Hedge Funds Weigh In On Sera Prognostics

A number of large investors have recently modified their holdings of SERA. Abel Hall LLC purchased a new stake in shares of Sera Prognostics during the 2nd quarter worth about $31,000. Wagner Wealth Management LLC acquired a new position in Sera Prognostics during the second quarter valued at approximately $34,000. Riverview Capital Advisers LLC purchased a new stake in Sera Prognostics during the second quarter worth approximately $35,000. Vanguard Personalized Indexing Management LLC purchased a new stake in Sera Prognostics during the third quarter worth approximately $38,000. Finally, Lido Advisors LLC acquired a new stake in Sera Prognostics in the 3rd quarter valued at $68,000. 54.64% of the stock is currently owned by hedge funds and other institutional investors.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.